Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China
ConclusionsT-DM1, as second-line therapy in the treatment of HER2-positive breast cancer, is not a cost-effective option in China. Given the significant clinical efficacy, an appropriate price reduction of T-DM1 is required to benefit more HER2-positive breast cancer patients.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | China Health | Drugs & Pharmacology | HER2 | Herceptin | Study | Xeloda